Spirulina and motor neurone disease.

ALS/MND pathobiology

ALS causes progressive degeneration of upper motor neurons (corticospinal tract) and lower motor neurons (anterior horn cells, brainstem nuclei) — leading to muscle weakness, wasting, spasticity, and eventually respiratory failure. Median survival from symptom onset is 2–5 years.

• SOD1 mutations (familial ALS):Mutations in Cu/Zn superoxide dismutase 1 cause misfolded SOD1 protein aggregation, mitochondrial dysfunction, and motor neuron toxicity — present in ~20% of familial ALS and ~2% of sporadic cases.
• TDP-43 aggregation:TAR DNA-binding protein 43 (TDP-43) forms cytoplasmic aggregates in >97% of sporadic ALS and frontotemporal dementia. TDP-43 normally regulates RNA processing in the nucleus — aggregation disrupts RNA homeostasis and triggers neurodegeneration.
• NOX2 microglial activation:Elevated NOX2 expression in spinal cord microglia is documented in ALS — generating sustained superoxide that damages motor neuron axons and dendrites. In SOD1 mouse models, microglial NOX2 deletion significantly slows disease progression and extends survival.
• Mitochondrial dysfunction:Impaired Complex I activity, elevated mitochondrial ROS, and calcium dysregulation in motor neuron mitochondria. Motor neurons have particularly high mitochondrial density and metabolic demands.

Iron in ALS: not the usual story

Unlike most conditions discussed on this site, iron status in ALS is not typically one of deficiency:

• CSF and brain iron levels are elevated in ALS — ferritin is an independent prognostic marker (higher CSF ferritin correlates with faster progression in some studies)
• Elevated serum ferritin is also common in ALS — as a reflection of systemic inflammation rather than true iron stores
• Excess free iron contributes to Fenton chemistry — generating hydroxyl radicals from hydrogen peroxide, exacerbating motor neuron oxidative stress
• Implication for spirulina:Spirulina’s iron provision is not a benefit in most ALS patients — and could be a concern if ferritin is already elevated. Check serum ferritin before starting. If ferritin >200 µg/L: spirulina iron is not indicated.

Phycocyanobilin and NOX2: the relevant mechanism

The microglial NOX2 finding in SOD1 mouse models is directly relevant to phycocyanobilin’s mechanism:

• Phycocyanobilin inhibits NOX2 in microglia — the same enzyme shown to accelerate motor neuron death in ALS models when genetically activated
• It crosses the blood-brain barrier and the blood-spinal-cord barrier in animal models, reaching motor neuron microenvironment
• Phycocyanin extract reduced oxidative stress markers in SOD1 mouse spinal cord in at least two published animal studies — but no clinical trials in ALS patients exist

The mechanistic case is one of the most biologically specific in neurodegeneration — but must be stated plainly: mouse models of ALS have failed to translate to human benefit for over 50 candidate interventions. The biological plausibility is real; clinical efficacy is unknown.

Nutritional context in ALS

ALS is a hypermetabolic state — energy expenditure increases as the disease progresses, while swallowing ability declines:

• Higher body weight (BMI) at diagnosis is independently associated with slower progression — nutritional support is not optional, it is part of ALS management
• Spirulina’s protein (6 g/10 g) in texture-modified formats may assist caloric density in dysphagia-modified diets alongside PEG tube decisions
• Antioxidant provision (vitamin E, C, and spirulina’s phycocyanin) is a commonly explored adjunct in ALS clinical care — no single antioxidant has shown survival benefit in trials, but nutritional antioxidant status is maintained as part of supportive care

Practical guidance

• Always discuss with the neurologist and multidisciplinary ALS team — they will have perspective on iron status, nutritional needs, and compatibility with riluzole (CYP1A2 metabolism — spirulina has minimal CYP interaction but confirmation is appropriate)
• Check serum ferritin before starting spirulina — if elevated (>200 µg/L), do not use spirulina as an iron source; if within normal range, spirulina iron is neutral to mildly beneficial
• 5–10 g/day is a reasonable dose range for adults with ALS — focus on phycocyanin as the primary mechanism of interest
• For dysphagia: capsules (opened and dispersed in food), smoothies thickened to appropriate IDDSI level, or puredé incorporation — discuss texture modification with speech therapist managing swallowing